Business News • PR NewsWire • Medivir - TMC435 Will Be Evaluated in a Phase II Combination Study With daclatasvir (BMS 790052) for HCV Genotype-1 Patients

Medivir - TMC435 Will Be Evaluated in a Phase II Combination Study With daclatasvir (BMS 790052) for HCV Genotype-1 Patients

Medivir - TMC435 Will Be Evaluated in a Phase II Combination Study With daclatasvir (BMS 790052) for HCV Genotype-1 Patients

HUDDINGE, Sweden, December 2, 2011 /PRNewswire/ -- Medivir AB (OMX:MVIR), the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that its development partner, Tibotec Pharmaceuticals, has entered into an...

View More : http://www.prnewswire.com/news-releases/medivir---tmc435-will-be-evaluated-in-a-phase-ii-combination-study-with-daclatas...

Releted News by prnewswire

American Greetings Makes it Even Easier to Find the Perfect Card this Holiday Season

Scotiabank reports record annual net income of $5.3 billion, and record revenues